Hadasit Bio-Holdings

Press Releases

Approval of Patent Registration in Japan - ProtAb Ltd.

Sep. 2, 2015

HBL - Hadasit Bio-Holdings Ltd.

(the “Company”)

September 2, 2015


To:                                                       To:

Israel Securities Authority                  Tel Aviv Stock Exchange Ltd. 

www.isa.gov.il                                    www.tase.co.il



Re: Receipt of Approval of Patent Registration in Japan - ProtAb Ltd.


The Company is pleased to announce that ProtAb Ltd., a subsidiary of the Company (hereinafter: “ProtAb”), has received approval to register a patent in Japan entitled:

Humanized Antibodies Specific for Hsp65-Derived Peptide-6 Methods and Uses Thereof (Japanese Patent No. 5781514) (hereinafter: the “Patent”).

The Patent refers to various sequences of antibodies that have undergone humanization, and include the prozomab antibody, at the forefront of ProtAb’s development efforts. Additionally, the Patent includes use of sequences as stated in treatment of patients with inflammatory bowel disease and rheumatoid arthritis.

The Patent was filed for approval for registration in a wide variety of countries, and was already approved for registration in the United States, China, and Australia.

The Patent is valid until September 2030.

The Company holds 69.54% of the share capital of ProtAb, which is engaged in the development of drugs for the treatment of inflammatory bowel disease (including Crohn’s disease and ulcerative colitis) and other autoimmune diseases.





HBL - Hadasit Bio-Holdings Ltd.

       By: Ms. Tamar Kfir, CEO


Press Releases Archive